Skip to main content
| News

Basel researchers developing universal cancer therapy

26.01.2021

Researchers from Basel are working on the development of a therapy in which pre-prepared immune cells can be used to treat any form of cancer immediately after diagnosis. A startup now intends to use 30 million US dollars in seed funding to finance the transition towards clinical development.

Researcher and entrepreneur Lucia Mori (img: University of Basel, Oliver Hochstrasser)

Dr. Lucia Mori from the Department of Biomedicine at the University of Basel is working on the development of a revolutionary cancer therapy. According to a press release issued by the university, this would represent substantial progress even in comparison with personalized immune therapies. While these facilitate high-precision treatment, they also take time. “Wouldn’t it be great if we could just reach into the freezer following a cancer diagnosis, and have a ready-made pack of immune cells ready to go? Regardless of the type of cancer?”, Mori states, highlighting the key advantage of her solution.

Together with her colleagues, Mori, who was born in Italy, identified cells in the human immune system that would be able to attack various types of cancer cells as part of her research in Basel – “the best place in the world for immunological research”, she claims. These MR1T cells are able to detect tumors and attack MR1, which is a protein carried by nearly all cancer cells. In the lab, MR1T cells can be customized so that that they can be used to combat a whole host of cancer indications.

“Our aim is to manipulate T cells from healthy donors in such a way that they can target the combinations of MR1 and other characteristic molecules on the surface of cancer cells”, Mori explains in the press release. As these characteristics are often shared by the same cancer types, the relevant therapies could be prepared in advance. For example, this kind of treatment could be used to fight breast, bowel and lung cancers.

The focus is now on transitioning to clinical development. For this, Mori co-founded the startup Matterhorn Biosciences, which has already raised 30 million US Dollars in seed financing from Versant Ventures.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 59

Do you have a question? We'd like to hear from you.